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Abstract: The use of activable cell-penetrating peptides (ACPPs) as molecular imaging probes 
is a promising new approach for the visualization of enzymes. The cell-penetrating function of a 
polycationic cell-penetrating peptide (CPP) is efficiently blocked by intramolecular electrostatic 
interactions with a polyanionic peptide. Proteolysis of a proteinase-sensitive substrate present 
between the CPP and polyanionic peptide affords dissociation of both domains and enables the 
activated CPP to enter cells. This ACPP strategy could also be used to modify antitumor agents 
for tumor-targeting therapy. Here, we aimed to develop a conjugate of ACPP with antitumor drug 
doxorubicin (DOX) sensitive to matrix metalloproteinase-2 and -9 (MMP-2/9) for tumor-targeting 
therapy purposes. The ACPP-DOX conjugate was successfully synthesized. Enzymatic cleavage 
of ACPP-DOX conjugate by matrix metalloproteinase (MMP)-2/9 indicated that the activation 
of ACPP-DOX occurred in an enzyme concentration–dependent manner. Flow cytometry and 
laser confocal microscope studies revealed that the cellular uptake of ACPP-DOX was enhanced 
after enzymatic-triggered activation and was higher in HT-1080 cells (overexpressed MMPs) 
than in MCF-7 cells (under-expressed MMPs). The antiproliferative assay showed that ACPP 
had little toxicity and that ACPP-DOX effectively inhibited HT-1080 cell proliferation. These 
experiments revealed that the ACPP-DOX conjugate could be triggered by MMP-2/9, which 
enabled the activated CPP-DOX to enter cells. ACPP-DOX conjugate may be a potential prodrug 
delivery system used to carry antitumor drugs for MMP-related tumor therapy.
Keywords: activable cell-penetrating peptide, matrix metalloproteinase, proteinase-  sensitive sub-
strate, cellular uptake, antiproliferative, enzymatic cleavage, tumor extracellular environment
Introduction
The use of cell-penetrating peptides (CPPs) has become one of the most popu-
lar and efficient techniques for achieving intracellular access. Commonly used 
CPPs include TAT, polyarginine, penetratin, and transportan. These CPPs have 
successfully delivered proteins,1 nucleic acids,2 small molecule therapeutics,3 
quantum dots,4 and magnetic resonance imaging contrast agents5 into cells. 
With the increased interest in CPP-mediated cargo delivery, CPPs have been 
applied in antitumor agent delivery. Doxorubicin (DOX) is a potent anthracy-
cline used for the treatment of various types of cancer. It causes cytotoxicity 
through topoisomerase II–mediated DNA breaks. Some publications6,7 have 
reported that CPP-DOX conjugates displayed excellent therapeutic efficacy for 
related tumor therapy. Efficient induction of apoptosis by CPP-DOX was found 
in the human breast cancer cell line MDA-MB-231.8,9 In addition, various CPP-
drug conjugates have also been developed to improve antitumor efficacy.10,11 
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However, the majority of known CPPs are not cell or tissue 
specific; CPPs and their attached therapeutic molecules are 
dispersed throughout almost all of the body irrespective 
of the method of administration. This property remains 
the major drawback for CPP application as drug delivery 
systems.12–14
The enzyme-sensitive substrate strategy is explorative 
and utilizes the stimulation of the unique tumor extracellular 
environment based on the principle of proteolysis. Proteolysis 
is a simple hydrolytic process that separates two adjacent 
amino acid residues at the amide bond and is triggered 
by proteases.15 Enzyme cleavable conjugates, containing 
enzyme-sensitive substrate, mainly take advantage of the 
selectivity and specificity of enzymes that are differentially 
active in the immediate environment of tumor cells.
Activable cell-penetrating peptides (ACPPs) containing 
polycationic CPPs, enzyme-sensitive substrate, and poly-
anionic inhibitory domains have been developed by Tsien’s 
group as molecular imaging probes in tumor detection and 
intraoperative guidance.16–20 The ACPPs are inactive in the 
circulation since the cell-penetrating function of CPP is 
efficiently blocked by intramolecular electrostatic interac-
tions with a polyanionic peptide. Proteolysis of a cleavable 
enzyme-sensitive substrate present between the CPP and 
polyanionic peptide by specific enzymes overexpressed on 
the disease site affords dissociation of both domains and 
enables the activated CPP to enter cells. This ACPP approach 
offers ways to address the major issue that CPPs lack cell 
specificity by means of the selective trigger of proteases in 
diseased tissue, and can be used for tumor-targeting therapy. 
It is interesting and meaningful to explore whether ACPP-
drug conjugates can be exploited for targeted drug delivery 
via enhanced targeting ability.
Here, we aimed to develop an ACPP-DOX conju-
gate sensitive to matrix metalloproteinases (MMPs) for 
tumor-targeting therapy purposes. MMPs are one type 
of frequently used cleavable enzyme that are associated 
with tumor   disease. The ACPP-DOX conjugate delivery 
system involves the polycationic domain (CPP), the cleav-
able MMP-2/9-sensitive substrate, the polyanionic domain 
(inhibitory or attenuating sequence), and DOX. The pro-
posed mechanism of intracellular access enhancement is 
exhibited in Figure 1A. This ACPP-DOX delivery system 
was temporarily inactive in circulation and in non- or 
under-expressed MMP tissue and subsequently activated 
by overexpressed MMP-2/9 in targets where cargo could 
be released. The design,   synthesis, and validation of the 
selectively triggered characterizations of this ACPP-DOX 
conjugate by extra MMPs and   endogenous MMPs were 
determined by high-performance liquid chromatography 
(HPLC), flow cytometry, and confocal microscopy. To 
examine the effect of ACPP-DOX, DOX, and ACPP on cell 
growth and viability, the antiproliferative assay was mea-
sured on HT-1080 and MCF-7 cells. The novel ACPP-DOX 
delivery system provides a new choice for MMP-related 
tumor therapy.
Materials and methods
Materials
DOX (.99%) was kindly donated by Hisun   Pharmaceutical 
Co,  Ltd,  (Zhejiang,  People’s  Republic  of  China). 
N-succinimidyl 3-maleimidopropionate (SMP; .98%) 
was purchased from Jiaxing Biomatrix Co, Ltd, (Zhejiang, 
People’s Republic of China). Trypsin was obtained from 
Amresco Inc (Solon, OH). 3-(4,5-dimethylthiazol-2-yl)-  2,5-
diphenyltetrazolium bromide (MTT) and collagenase IV were 
purchased from Sigma-Aldrich (St Louis, MO).   Penicillin, 
streptomycin, and Hoechst 33258 were provided by   Macgene 
Co, Ltd, (Beijing, People’s Republic of China), while 
4-aminophenylmercuric acetate (APMA) was purchased 
from Merck Co, Ltd, (Darmstadt, Germany). MMP-2 was 
procured from PeproTech EC Ltd (London, UK). All other 
chemicals were of analytic or HPLC grade.
The ACPP (H2 N-DGGDGGDGGDGPLGLAGrrrrrrrrrC-
COOH [the uppercase letters represent L-amino acids, while 
the lowercase letters represent D-amino acids]) was custom 
synthesized via a standard Fmoc solid-phase peptide synthe-
sis method by Shanghai GL Biochem Co, Ltd, (Shanghai, 
People’s Republic of China). The purity of ACPP was 97.9%. 
The correct product was confirmed by electrospray ioniza-
tion mass spectroscopy (ESI-MS): m/z, 2895.2 (calculated), 
2895.57 (observed, [M+3H]3+: 966.19), 2896.18 (observed, 
[M+2H]2+: 1449.09).
Cell lines
HT-1080 (human fibrosarcoma) cells were purchased from 
the Cell Culture Centre, Peking Union Medical College 
  (Beijing, People’s Republic of China). The cells were 
cultured in Minimum Essential Medium with Earle’s salts, 
L-glutamine, nonessential amino acid (Macgene, Beijing, 
People’s Republic of China), 10% fetal bovine serum (FBS), 
100 units/mL penicillin, and 100 µg/mL streptomycin.
MCF-7 (human breast adenocarcinoma) cells were obtained 
from the Institute of Hematology and Blood Diseases Hospital 
(Tianjin, China). The cells were maintained in Dulbecco’s 
Modified Eagle’s Medium with glucose, sodium pyruvate, 
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L-glutamine, and 4-(2-hydroxyethyl)-1-piperazineethane  -
sulfonic acid   (Macgene, Beijing, People’s Republic of China) 
  supplemented with 10% FBS, 100 units/mL penicillin, and 
100 µg/mL streptomycin.
All the cells were cultured in an incubator maintained 
at 37°C with 5% CO2 under fully humidified conditions. 
All experiments were performed on cells in the exponential 
growth phase.
Synthesis of ACPP-DOX conjugate
ACPP-DOX conjugate was synthesized by coupling ACPP 
with DOX using a linker of SMP. Thus, DOX-SMP was pre-
pared first. The general synthetic scheme is depicted in Fig-
ure 1B. Briefly, DOX (43.5 mg, 1 Eq), SMP (22.0 mg, 1.1 Eq), 
and triethylamine (TEA; 2 Eq) were dissolved in 8 mL of 
dimethylformamide (DMF) and stirred at room temperature 
for 2 hours, while the progress of the reaction was monitored 
by thin-layer chromatography (TLC; chloroform:methanol: 
  ammonia = 70:30:3). The reaction solution was treated with 
50 mL of cold anhydrous diethyl ether and the resulting pre-
cipitate was washed twice with 5 mL of anhydrous diethyl 
ether. The red solid that was obtained was separated from 
the solvent by   centrifugation. The product was dried to give 
a 64.3% yield in red crystals.
Secondly, the ACPP-DOX was synthesized. DOX-SMP 
(2.6 mg, 1 Eq), ACPP (10 mg, 1 Eq), TEA (10 µL, 21 Eq), and 
1 mL of DMF were mixed and stirred at room temperature 
for 2 hours, while the progress of the reaction was monitored 
using TLC and HPLC. The reaction solution was treated 
with 10 mL of cold anhydrous diethyl ether and the result-
ing precipitate was washed twice with 5 mL of anhydrous 
diethyl ether. The resulting red solid was separated from the 
solvent by centrifugation, and then the product was dried to 
give a 78.8% yield in red crystals.
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Figure 1 (A) Proposed schematic diagram of ACPP-DOX conjugate for antitumor drug delivery. ACPP-DOX conjugate is inactivated initially and circulates freely in 
vivo. When the ACPP-DOX conjugate accesses the tumor tissue, it is triggered and activated by overexpressed extracellular MMPs (MMP-2/9). The CPP-DOX releases 
and translocates into cells. The ACPP-DOX conjugate includes a cargo of doxorubicin, polycational CPP, polyanional attenuating peptides, and MMP-specific substrates. 
(B) Synthesis scheme of ACPP-DOX conjugates: (a) doxorubicin (DOX), (b) N-succinimidyl-3-maleimidopropionate (SMP), (c) DOX-SMP, (d) ACPP, an activatable cell-
penetrating peptide. (e) ACPP-DOX, a derivative of DOX linked with the ACPP. (C) 1h-NMR spectrum of DOX-SMP. (D) FT-IR spectra of SMP, DOX, and DOX-SMP.
Abbreviations: ACPP-DOX, activable cell-penetrating peptide–doxorubicin; CPP, cell-penetrating peptide; MMP, matrix metalloproteinase.
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Enzymatic-triggered cleavage  
of ACPP-DOX by MMPs
To analyze the enzymatic cleavage of the matrix metallopro-
teinase (MMP)-sensitive conjugates, ACPP-DOX cleavage 
was studied in the presence of MMP-2/9. Collagenase IV 
(containing MMP-2/9) was activated with the 2.5 mM APMA 
solution for 1 hour at 37°C. ACPP-DOX stock solution was 
mixed with activated collagenase IV and incubated at 37°C. 
The aliquots were removed between 1 hour and 4 hours and 
analyzed by HPLC. The HPLC system was equipped with 
a Waters 2487 Dual Wavelength Absorbance Detector and 
1525 Pump (Milford, MA), and the wavelength was set at 
220 nm. To determine ACPP-DOX conjugate and hydrolysate 
simultaneously, a gradient was used as the eluent. The flow 
was 1 mL/min with a mixed mobile phase that included 
solvent A (water with 0.1% trifluoroaceticacid [TFA]) and 
solvent B (acetonitrile with 0.1% TFA). The gradient was as 
follows: 0–15 minutes, from 95% solvent A to 70% solvent A; 
15–25 minutes, from 70% solvent A to 100% solvent B. This 
system was sustained at 100% solvent B for 5 minutes.
Cellular uptake
Based on confirmed reports, MCF-7 cells are known to 
under-secrete MMP-2/9.21,22 MCF-7 cells were selected as 
low MMP-secreting tumor cell types to investigate the uptake 
of activable conjugates after extra MMPs trigger cleavage. 
HT-1080 cells were used as overexpressed MMP-2/916,23 
tumor cell types to study the cellular uptake of activable 
ACPP-DOX after cell-secreted MMPs trigger cleavage. 
Innate fluorescence of DOX allowed us to use flow cytometry 
and confocal microscopy to study penetration and localiza-
tion of free or conjugated DOX.
Collagenase IV or MMP-2 was activated at 37°C with 
the 2.5 mM APMA solution. MCF-7 cells were seeded into 
six-well plates (2 × 105 cells per well) and allowed to grow for 
24 hours. These cells were washed with phosphate-buffered 
saline (PBS; 0.1 M, pH 7.4) and preincubated with different 
concentrations of activated enzyme solutions for 1 hour. Then 
the supernatants were removed and discarded, and the cells 
were incubated with 5 µM of ACPP-DOX dissolved in 1 mL 
of blank culture for 12 hours. After the incubation, the cells 
were washed three times with PBS (0.1 M, pH 7.4). A total 
of 1 mL of 0.25% trypsin solution was added, and the cells 
were detached from cell culture by incubation for 3 minutes 
at 37°C. The cell suspensions were centrifuged for 3 minutes 
and resuspended in 0.5 mL PBS. Single-cell suspensions 
were prepared by filtration through a 300-mesh filter. Finally, 
the cells suspended in PBS were subjected to flow cytometry 
analysis using a FACScan (Becton Dickinson, San Jose, CA). 
The cells associated with DOX or ACPP-DOX were excited 
with an argon laser at 488 nm and fluorescence was detected at 
588 nm. Files of 10,000 gated events were collected and ana-
lyzed with the FACStation software (Cellquest 3.3) program.
MCF-7 and HT-1080 cells were seeded into six-well plates 
(2 × 105 cells per well) and allowed to grow for 24 hours. 
The cells were incubated with free DOX or ACPP-DOX at 
an equal concentration of 10 µM for   different periods. After 
the incubation, the drug solutions were removed and the 
cells were washed three times with PBS (0.1 M, pH 7.4). 
  Subsequently, the same flow cytometry procedure described 
above was performed for determining cellular uptake.
Following the culture of MCF-7 and HT-1080 cells for 
24 hours on a petri dish, free DOX or ACPP-DOX at a con-
centration of 5 µM was added to each dish and incubated at 
37°C. The medium was removed and discarded, and the cells 
were washed with PBS (0.1 M, pH 7.4), followed by fixing 
with 4% paraformaldehyde for 10 minutes. Nuclear staining 
was performed by Hoechst 33258 for 15 minutes, and the 
fluorescent images of cells were analyzed using a laser scan-
ning confocal microscope (TCS SP5; Leica Microsystems 
GmbH, Wetzlar, Germany).
Antiproliferative activity against  
MCF-7 and hT-1080 cells
The antiproliferative activity of DOX, ACPP-DOX, and 
ACPP was analyzed by the MTT method.24 MCF-7 and 
HT-1080 cells were seeded at a density of 2 × 104 cells/well 
in 96-well plates. After culturing for 24 hours in an incuba-
tor (37°C, 5% CO2), 20 µL of various sample solutions in a 
concentration range of 1 µM to 100 µM were added to each 
well, and the plates were incubated for 24 hours. Next, 20 µL 
of MTT solution (5.0 mg/mL) was added to each well, and 
the plates were incubated for another 4 hours. After that, the 
MTT medium was replaced by 200 µL of dimethyl sulfoxide 
(DMSO) in each well, and the mixture was shaken at room 
temperature to dissolve the reacted dye. The optical density 
was measured at 570 nm using a microplate reader (Bio-Rad, 
Hercules, CA). Cell viability = (A-B)/A × 100%, where A 
was the absorbance of the cells incubated with the culture 
medium and B was the absorbance of the cells incubated with 
the DOX, ACPP-DOX, or ACPP, respectively. All samples 
were evaluated in sextuplicate.
Data analysis
Data were expressed as the mean ± standard deviation, 
and statistical analysis was performed using an unpaired 
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  Student’s t-test. Data were considered significantly different   
at P , 0.05.
Results and discussion
Design and synthesis of ACPP-DOX
For tumor cells to invade and metastasize, the first barrier to 
overcome is the basement membrane, which is composed of 
type IV collagen. Type IV collagen is susceptible to degrada-
tion by MMP-2 and MMP-9.25
H2 N-DGGDGGDGGDGPLGLAG-rrrrrrrrrC-COOH 
was designed as the ACPP. The ACPP includes three units: 
the cell-penetrating domain (polyarginine, R9), the cleavable 
enzyme-specific substrate domain of MMP-2/9 (PLGLAG), 
and the attenuating peptides domain   (DGGDGGDGGDG). 
Some research indicates that L-polyarginine (R9) was 
20-fold more efficient than Tat(49-57) at cellular uptake as 
determined by Michaelis–Menten kinetic analysis, and the 
D-polyarginine (R9) exhibited an even greater enhancement 
of uptake rate (.100-fold) than the R9.26 PLGLAG was 
considered a remarkably sensitive or cleavable sequence 
by MMP-2 and MMP-9.19,27 To prevent CPP distribution 
toward normal cells, polyanional DGGDGGDGGDG is 
added to the molecule as an attenuating or shielding motif. 
The C-terminal cysteine is a linker designed to couple eas-
ily with the maleimide group. Thus, the ACPP peptide is 
temporarily inactivated, and subsequent activation is trig-
gered by overexpressed MMPs in tumor targets where the 
CPP will be released.
DOX-SMP was synthesized by a reaction between the 
3′ amino group of the daunosamine sugar of DOX and an 
active ester group of SMP. TEA was added to remove the 
hydrochloride salt and also to maintain basic conditions to 
favorably generate DOX-SMP. DOX-SMP HPLC   analysis: 
93.5%; yield: 64.3%; matrix-assisted laser desorption 
ionization orthogonal time of flight mass spectrometry 
(MALDI-TOF-MS) (m/z, [M+Na]+): 717.6 (calculated), 
715.95 (observed). MALDI-TOF-MS (m/z, [M+K]+): 733.6 
(calculated), 732.03 (observed). ESI-MS (m/z, [M+Na]+): 
717.6 (calculated), 717.1 (observed).
The  1H-NMR spectrum of DOX-SMP in DMSO-D6 
(Bruker, 400M; Zurich, Switzerland) is shown in Figure 1C. 
O-methylation of  the 4-position and 14-CH2 in the DOX-SMP 
molecule were seen at 3.972 ppm and 4.55 ppm (single peak), 
respectively. The 6-OH and 11-OH of DOX-SMP were also 
observed at 14.026 ppm and 13.266 ppm, respectively. Chemi-
cal shifts between 7.5 and 8.0 ppm were assigned as 1H-3H 
of the benzene. Furthermore, an obvious single peak at 6.952 
ppm was a characteristic shift representing the 1′-H and 2′-H 
of the maleimide group. The 1H-NMR results indicated that 
the compound was in agreement with the predicted structure 
of   DOX-SMP. In addition, the Fourier transform infrared (FT-
IR) spectrum of DOX-SMP (Figure 1D) showed that a single 
peak at 3369.88 cm–1 was attributed to a hydrogen   skeletal 
vibration of a secondary amide group. The appearance of a 
secondary amide showed that DOX and SMP were coupled 
by an amide linkage. All of the above characteristics demon-
strated that DOX-SMP was synthesized successfully.
The C-terminal amino acid of the ACPP peptide is a 
cysteine, which provides a chemically reactive thiol group for 
drug conjugation. DOX-SMP can be covalently attached to the 
cysteine sulfur of ACPP with maleimide by way of a Michael 
addition (nucleophilic addition) to   produce ACPP-DOX. 
HPLC analysis: 95.3%; yield: 78.8%;   MALDI-TOF-MS 
(m/z, [M-H]-): 3588.8 (calculated), 3587.26 (observed). Thus, 
according to the well-designed synthetic route and proven by 
the MALDI-TOF-MS result, a derivative of DOX linked with 
ACPP (ACPP-DOX) was obtained successfully.
Enzymatic-triggered cleavage  
of ACPP-DOX by MMPs
ACPP-DOX incorporates a MMP-2/9-sensitive substrate; 
subsequently, the triggered cleavage study was performed 
through an extra enzymatic digestion experiment on dif-
ferent [MMPs]/[ACPP-DOX] ratios for 4 hours. As MMP 
concentration decreased, ACPP-DOX cleavage increased 
proportionally (Figure 2). The half-lives of ACPP-DOX 
cleavage were approximately 0.6 hour, 0.9 hour, 1.1 hours, 
and 2.5 hours with a series of (MMPs)/(ACPP-DOX) ratios 
of 0.463:1, 0.288:1, 0.173:1, and 0.114:1, respectively. In 
contrast, almost no cleavage was observed for ACPP-DOX 
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Figure  2  Enzymatic-triggered  cleavage  of  ACPP-DOX  conjugate  by  MMPs  in 
different ratios. 
Note:  (MMPs)/(ACPP-DOX)  (w/w)  of  (A)  0.463:1  (B)  0.288:1  (C)  0.173:1 
(D) 0.114:1, and (E) absence of MMP treatment. 
Abbreviations: ACPP-DOX, activable cell-penetrating peptide–doxorubicin; MMP, 
matrix metalloproteinase.
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in the absence of MMPs after 3.5 hours of incubation. The 
experiment results proved that MMP-2/9 can cleave the 
ACPP and the scissor rate of ACPP-DOX was related to 
the concentration of MMP-2/9. MMP concentration was 
  obviously related to the degree of cleavage; more cleavage 
was also found in MMP-activated imaging nanoparticles with 
the increase of extra MMPs.28 In our previous experiments, 
the hydrolysis fragments of ACPP have been detected by 
MALDI-TOF-MS and it was proved that the ACPP could 
be cleaved by MMP-2/9 at target site.29
Enhancing cellular uptake after enzymatic-
triggered cleavage of ACPP-DOX
When ACPP-DOX is scissored and activated to CPP-DOX 
by MMP-2/9, cellular uptake of CPP-DOX is expected to be 
enhanced due to the effect of CPP penetration. MCF-7 cells 
were used as a model system of under-expressed MMP-2/9 
to study the effect of extra MMP-triggered cleavage of 
ACPP-DOX on cellular uptake. As shown in Figure 3A, 
MCF-7 cell–associated fluorescence was significantly higher 
(5.1- or 5.6-fold) in either group after ACPP-DOX activa-
tion by MMP-2/9 than that of the group with absence of 
collagenase (P , 0.001). It was obvious that the increase in 
MMP-2/9 concentration from 20 to 200 µg/mL resulted in 
stronger uptake of DOX (P , 0.05). MMP-2 pretreatment 
was performed in MCF-7 cells (Figure 3B). ACPP-DOX 
showed an approximately 3.4-fold higher uptake when the 
concentration of MMP-2 was 100 ng/mL compared with the 
group without MMP-2 (P , 0.001). In contrast, 20 ng/mL 
of MMP-2 treatment had a lower uptake of ACPP-DOX 
compared to the group treated with 100 ng/mL of MMP-2 
(P , 0.001).
HT-1080 cells were used as a model system of overex-
pressed MMP-2/9 to study the effect of triggered cleavage 
of ACPP-DOX on cellular uptake. As shown in Figure 3C, 
fluorescence intensity of free DOX in both MCF-7 and 
HT-1080 cells was similar after 8 hours of incubation. 
  Cellular uptake properties of free DOX were in accordance 
with the reported results and this might be responsible for 
transportation into cells by the passive diffusion mecha-
nism.30,31 Compared with free DOX, ACPP-DOX displayed 
lower uptake into both cells. However, it was noteworthy 
that the uptake intensity of ACPP-DOX was significantly 
higher in HT-1080 cells than in MCF-7 cells after 24 hours 
of   incubation. After 48 hours of incubation, the uptake 
intensity of ACPP-DOX in HT-1080 cells was 3.3-fold 
higher than that in MCF-7 cells. This implied that ACPP-
DOX was more sensitive to HT-1080 than to MCF-7 cells, 
and the sensitivity corresponded with the HT-1080 cell 
over-secreted MMPs.
The intracellular trafficking of DOX and ACPP-DOX 
was studied in HT-1080 and MCF-7 cells using confo-
cal laser scanning microscopy. Different incubation times 
were employed from 2 to 8 hours (Figure 3D). The uptake 
was weak in both HT-1080 and MCF-7 cells treated with 
  ACPP-DOX for 2 hours. The fluorescence emerged at 4 hours 
and gradually increased with longer incubation. The fluores-
cence intensity was significantly stronger in HT-1080 cells 
than in MCF-7 cells over time, which meant that more DOX 
entered HT-1080 cells. For DOX, its fluorescence was clearly 
observed in HT-1080 and MCF-7 cells after incubation for 
only 2 hours, a longer incubation time (4 or 8 hours) resulted 
in stronger fluorescence.
It was noteworthy that the degree of uptake enhance-
ment was obviously related to the extra MMP-2/9 trigger 
on MCF-7 cells and the endogenous MMP trigger on 
HT-1080 cells. In addition, the higher uptake of nanostruc-
tured lipid carriers incorporating ACPP on HT-1080 cells 
was inhibited in the presence of GM6001 (Enzo Life 
  Sciences, Inc, Farmingdale, NY), a known MMP inhibitor 
(data not shown). These phenomena were in accordance with 
extra enzymatic cleavage analysis as determined by HPLC 
 ( Figure 2) and suggested that the cleavage was specifically 
by MMPs.16,32–34 Enhanced cellular uptake is important after 
triggered activation especially for some poor membrane-
penetrating candidates.
Antiproliferative activity
To examine the effect of ACPP-DOX, DOX, and ACPP on 
cell growth and viability, the potential antiproliferative activi-
ties were measured by the MTT method on HT-1080 and 
MCF-7 cells. For parallel comparison, cells were incubated 
with ACPP-DOX, DOX, and ACPP at a series of equivalent 
concentrations from 1 to 100 µM. As shown in Figure 4, the 
ACPP did not show any obvious antiproliferative activities 
in HT-1080 and MCF-7 cells after 24 hours of incubation, 
which revealed that the ACPP was relatively safe. With 
increased concentration of DOX, the antiproliferative activi-
ties of free DOX increased significantly on both MCF-7 and 
HT-1080 cells, but the ACPP-DOX conjugate displayed 
stronger antiproliferative activities on HT-1080 than on 
MCF-7 cells. Namely, the ACPP-DOX conjugate was more 
effective against HT-1080 than MCF-7 cells correlating to 
the level of MMPs, despite the fact that DOX had almost 
equal cytotoxicity both on HT-1080 and MCF-7 cells with 
no correlation to the proteases.
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Figure 3 (A) The uptake intensity of MCF-7 cells after treatment with ACPP-DOX conjugate in the absence (-) or presence of extra collagenase IV at concentrations 
of 20 µg/mL and 100 µg/mL. (B) The uptake intensity of MCF-7 cells after treatment with ACPP-DOX conjugate in the absence (-) or presence of extra MMP-2 at 
concentrations of 20 ng/mL and 200 ng/mL. (C) Cellular uptake intensity–time curve of DOX and ACPP-DOX in MCF-7 and hT-1080 cells at different incubation times. (D) 
Confocal microscopy images of ACPP-DOX or DOX incubated with hT-1080 and MCF-7 cells at 37°C for 0 hour–8 hours. 
Notes: Red represents fluorescence of DOX. Blue represents fluorescence of Hoechst 33258 for nuclei staining. Scale bars: 100 µm. *P , 0.001; #P , 0.05; ns = no 
significance. 
Abbreviations: DOX, doxorubicin; ACPP-DOX, activable cell-penetrating peptide–doxorubicin; MMP-2, matrix metalloproteinase-2.
The increased cytotoxicity of ACPP-DOX   conjugate 
toward HT-1080 cells was probably due to released 
  CPP-DOX and enhanced cell uptake by the activation of 
overexpressed MMP-2/9 in this cell type. Our previous 
cell-uptake studies of CPP-cargos have demonstrated that 
polyarginine peptides as well as CPP-avidin can easily enter 
cells and tissues.12   Abundant research proves that CPPs could 
transport cargos into cells.1–5,35–37 Numerous small molecule 
  chemotherapeutics, such as taxol,38 methotrexate,10 and 
DOX8,11 have shown improved activity when conjugated to 
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a CPP. Remarkably, even though a CPP-drug conjugate may 
show less activity in a purified biochemical system, highly 
efficient cellular uptake can overcome this shortfall, because 
CPP-drug conjugates can effectively increase the intracellular 
concentrations of drug molecules and this can counteract 
decreases in drug activity that result from conjugation.10,14 
These results indicate that ACPP-drug conjugate delivery 
strategy provides potential for tumor-targeted delivery of 
antitumor therapeutics by triggered activation.
Conclusion
The ACPP approach could potentially address the main issue 
that CPPs lack cell specificity by means of the selective 
trigger of proteases at the tumor targets. To our knowledge, 
reported ACPPs were mostly designed as imaging agents. 
We synthesized ACPP-DOX conjugate in good purity and 
yields. The proteolytic activation of the ACPP-DOX conju-
gate occurs in an enzyme concentration–dependent manner. 
The enhanced cellular uptake and antiproliferative activity 
of ACPP-DOX conjugate was observed after MMP-senstive 
activation and revealed that ACPP-DOX conjugate has tar-
geting ability for tumor cells rich in MMP-2/9. The ACPP-
drug conjugate delivery system triggered by protease is a 
promising approach for the treatment of some tumors with 
overexpression of MMP-2 or MMP-9.
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